{
  "source": {
    "document_id": "Dransfield-2020-Effect of Zephyr Endobronchial",
    "ingest_date": "2025-08-08T11:35:14.407293+00:00",
    "trial_registration_id": "NCT01796392",
    "pmid": "",
    "doi": "10.1513/AnnalsATS.201909-666OC"
  },
  "document": {
    "metadata": {
      "title": "Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year: Results from a Randomized Clinical Trial",
      "year": 2020,
      "authors": [
        "Mark T. Dransfield",
        "Justin L. Garner",
        "Surya P. Bhatt",
        "Dirk-Jan Slebos",
        "Karin Klooster",
        "Frank C. Sciurba",
        "Pallav L. Shah",
        "Nathaniel T. Marchetti",
        "Richard D. Sue",
        "Shawn Wright",
        "Hiram Rivas-Perez",
        "Tanya A. Wiese",
        "Momen M. Wahidi",
        "Hugo Goulart de Oliveira",
        "Brian Armstrong",
        "Sri Radhakrishnan",
        "Narinder S. Shargill",
        "Gerard J. Criner"
      ],
      "journal": "Annals of the American Thoracic Society",
      "doi": "10.1513/AnnalsATS.201909-666OC",
      "pmid": ""
    },
    "sections": {
      "abstract": "Rationale: Bronchoscopic lung volume reduction with Zephyr Valves improves lung function, exercise tolerance, and quality of life of patients with hyperinflated emphysema and little to no collateral ventilation. Objectives: Post hoc analysis of patient-reported outcomes (PROs), including multidimensional measures of dyspnea, activity, and quality of life, in the LIBERATE study are reported. Methods: A total of 190 patients with severe heterogeneous emphysema and little to no collateral ventilation in the target lobe were randomized 2:1 to the Zephyr Valve or standard of care. Changes in PROs at 12 months in the two groups were compared: dyspnea with the Transitional Dyspnea Index (TDI), focal score; the COPD Assessment Test (CAT; breathlessness on hill/stairs); Borg; the EXACT-PRO, dyspnea domain; activity with the TDI, magnitude of task/effort/functional impairment, CAT (limited activities), and the St. George’s Respiratory Questionnaire (SGRQ), activity domain; and psychosocial status with the SGRQ, impacts domain, and CAT (confidence and energy). Results: At 12 months, patients using the Zephyr Valve achieved statistically significant and clinically meaningful improvements in the SGRQ; CAT; and the TDI, focal score, compared with standard of care. Improvements in the SGRQ were driven by the impacts and activity domains (P < 0.05 and P < 0.001, respectively). Reduction in CAT was through improvements in breathlessness (P < 0.05), energy level (P < 0.05), activities (P < 0.001), and increased confidence when leaving home (P < 0.05). The TDI measures of effort, task, and functional impairment were uniformly improved (P < 0.001). The EXACT-PRO, dyspnea domain, was significantly improved in the Zephyr Valve group. Improvements correlated with changes in residual volume and residual volume/TLC ratio. Conclusions: Patients with severe hyperinflated emphysema achieving lung volume reductions with Zephyr Valves experience improvements in multidimensional scores for breathlessness, activity, and psychosocial parameters out to at least 12 months. Clinical trial registered with www.clinicaltrials.gov (NCT01796392).",
      "methods": "The multicenter study conducted under a U.S. Food and Drug Administration-approved Investigational Device Exemption for the Zephyr Valve was approved by the respective institutional review boards or ethics committees at each site, and all participating subjects were provided written informed consent. Multiple discrete and validated self-administered questionnaires were completed at baseline and follow-up visits. These included: for dyspnea, the TDI, focal score; Borg scale of perceived exertion; EXACT-PRO diary, dyspnea domain; and the CAT question regarding breathlessness on hill/stairs; for activity, the TDI, magnitude of task, magnitude of effort, and functional impairment; the CAT questions regarding limited activities; and the SGRQ, activity domain; and, for psychosocial status, the SGRQ, impacts domain, and the CAT questions regarding confidence and energy. Neither the study participants nor the assessing physicians were blinded to the randomization. At follow-up assessments, study participants were not reminded of, and thus were not aware of, their baseline scores. Statistical analyses: Inferential statistics for the SGRQ domains, the TDI domains, the mMRC Dyspnea Scale, CAT individual questions, Borg, and EXACT-PROs were post hoc. Continuous variables were compared with the Wilcoxon rank sum (for nonparametric data) or an analysis of covariance with the respective baseline value as the covariate (for parametric data), and categorical variables were compared with the Fisher exact test. Statistical significance was determined at the P < 0.05 level.",
      "results": "A total of 190 patients were randomized 2:1 (128 Zephyr Valve; 62 standard of care). Twelve subjects did not complete the 12-month assessments (9 Zephyr Valve; 3 standard of care). At 12 months, multiple measures of dyspnea showed statistically significant improvements in the Zephyr Valve group compared with standard of care: mMRC Dyspnea Scale change (-0.5 ± 1.17 vs 0.3 ± 1.03; Δ -0.8; P < 0.001), TDI focal score change (2.3 ± 5.25 vs -2.0 ± 4.35; Δ 4.3; P < 0.001), Borg after 6MWT change (-0.45 ± 2.24 vs 0.42 ± 2.37; Δ -0.87; P < 0.001), EXACT-PRO dyspnea domain change (-5.5 ± 18.6 vs 3.3 ± 11.25; Δ -8.8; P = 0.002), and CAT Q4 breathlessness change (-0.5 ± 1.56 vs 0.1 ± 1.20; Δ -0.6; P = 0.002). Activity measures favored Zephyr Valve: 6MWD change (12.98 ± 81.54 m vs -26.33 ± 81.50 m; Δ 39.3 m; P = 0.002), TDI magnitude of task (0.8 ± 1.8 vs -0.6 ± 1.5; Δ 1.4; P < 0.001), TDI magnitude of effort (0.8 ± 1.9 vs -0.7 ± 1.5; Δ 1.5; P < 0.001), TDI functional impairment (0.7 ± 1.8 vs -0.7 ± 1.6; Δ 1.4; P < 0.001), CAT Q5 activity (-0.7 ± 1.7 vs 0.0 ± 1.3; Δ -0.7; P < 0.001), and SGRQ activity domain (-12.0 ± 21.46 vs 0.70 ± 14.31; Δ -12.7; P < 0.001). Psychosocial status improved with Zephyr Valve versus standard of care: SGRQ total (-7.55 ± 15.71 vs -0.50 ± 15.50; Δ -7.05; P = 0.004) and SGRQ impacts domain (-9.58 ± 19.00 vs 0.14 ± 17.34; Δ -9.72; P = 0.004). Responder analyses showed higher proportions with clinically meaningful improvements for mMRC and TDI focal score in the Zephyr Valve group."
    }
  },
  "pico": {
    "population": {
      "text": "Adults with severe heterogeneous emphysema, hyperinflation, and little to no collateral ventilation in the target lobe.",
      "inclusion_criteria": [
        "Severe heterogeneous emphysema",
        "Hyperinflation",
        "Little to no interlobar collateral ventilation in the target lobe assessed using Chartis System"
      ],
      "exclusion_criteria": []
    },
    "intervention": {
      "text": "Zephyr Endobronchial Valve",
      "details": "Bronchoscopic lung volume reduction with placement of Zephyr one-way endobronchial valves in a target lobe selected based on heterogeneity and collateral ventilation assessment."
    },
    "comparison": {
      "text": "Standard of care",
      "details": "Optimized medical management without valve placement."
    },
    "outcomes": [
      {
        "name": "Dyspnea, activity, and psychosocial patient-reported outcomes at 12 months (e.g., TDI focal score, mMRC, Borg, EXACT-PRO dyspnea, CAT items; SGRQ domains; 6MWD)",
        "type": "secondary",
        "umls_cui": ""
      }
    ]
  },
  "design": {
    "study_type": "Randomized controlled trial",
    "allocation": "randomized (2:1)",
    "blinding": "open-label",
    "sites_count": null,
    "countries": [
      "US",
      "UK",
      "Netherlands",
      "Brazil"
    ],
    "sample_size": {
      "planned": null,
      "enrolled": 190,
      "analyzed": null
    },
    "analysis_populations": [
      {
        "name": "ITT",
        "description": "All randomized participants",
        "n": 190
      },
      {
        "name": "Completers_12M",
        "description": "Participants who completed the 12-month assessments",
        "n": 178
      }
    ]
  },
  "arms": [
    {
      "arm_id": "intervention",
      "name": "Zephyr Endobronchial Valve",
      "n_randomized": 128,
      "n_analyzed": null,
      "n_completed": 119
    },
    {
      "arm_id": "control",
      "name": "Standard of Care",
      "n_randomized": 62,
      "n_analyzed": null,
      "n_completed": 59
    }
  ],
  "outcomes_normalized": [
    {
      "concept_id": "mmrc_change_12m",
      "name": "mMRC Dyspnea Scale change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -0.5,
            "sd": 1.17,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 0.3,
            "sd": 1.03,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -0.8,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc); primary/secondary endpoints used multiple imputation"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "mMRC Dyspnea Scale change from baseline at 12 months: -0.5 ± 1.17 (Zephyr) vs 0.3 ± 1.03 (SoC); Δ -0.8; P < 0.001"
      }
    },
    {
      "concept_id": "tdi_focal_change_12m",
      "name": "Transitional Dyspnea Index (TDI) focal score change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": 2.3,
            "sd": 5.25,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": -2.0,
            "sd": 4.35,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": 4.3,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": true
      },
      "analysis": {
        "model": "ANCOVA",
        "adjusted": true,
        "covariates": [
          "baseline value"
        ],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "TDI focal score change: 2.3 ± 5.25 (Zephyr) vs -2.0 ± 4.35 (SoC); Δ 4.3; P < 0.001"
      }
    },
    {
      "concept_id": "borg_post6mwt_change_12m",
      "name": "Borg dyspnea score after 6MWT change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -0.45,
            "sd": 2.24,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 0.42,
            "sd": 2.37,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -0.87,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "Borg after 6MWT change: -0.45 ± 2.24 (Zephyr) vs 0.42 ± 2.37 (SoC); Δ -0.87; P < 0.001"
      }
    },
    {
      "concept_id": "exact_pro_dyspnea_change_12m",
      "name": "EXACT-PRO dyspnea domain change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -5.5,
            "sd": 18.6,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 3.3,
            "sd": 11.25,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -8.8,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.002,
        "p_operator": "=",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "EXACT-PRO dyspnea domain change: -5.5 ± 18.6 (Zephyr) vs 3.3 ± 11.25 (SoC); Δ -8.8; P = 0.002"
      }
    },
    {
      "concept_id": "cat_q4_breathlessness_change_12m",
      "name": "CAT Q4 (breathlessness on hill/stairs) change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -0.5,
            "sd": 1.56,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 0.1,
            "sd": 1.2,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -0.6,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.002,
        "p_operator": "=",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "CAT Q4 breathlessness change: -0.5 ± 1.56 (Zephyr) vs 0.1 ± 1.20 (SoC); Δ -0.6; P = 0.002"
      }
    },
    {
      "concept_id": "sixmwd_change_12m",
      "name": "6-minute walk distance change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "m",
      "unit_canonical": "meter",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": 12.98,
            "sd": 81.54,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": -26.33,
            "sd": 81.5,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": 39.3,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.002,
        "p_operator": "=",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "6MWD change: 12.98 ± 81.54 m (Zephyr) vs -26.33 ± 81.50 m (SoC); Δ 39.3 m; P = 0.002"
      }
    },
    {
      "concept_id": "tdi_task_change_12m",
      "name": "TDI magnitude of task change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": 0.8,
            "sd": 1.8,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": -0.6,
            "sd": 1.5,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": 1.4,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": true
      },
      "analysis": {
        "model": "ANCOVA",
        "adjusted": true,
        "covariates": [
          "baseline value"
        ],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "TDI magnitude of task change: 0.8 ± 1.8 (Zephyr) vs -0.6 ± 1.5 (SoC); Δ 1.4; P < 0.001"
      }
    },
    {
      "concept_id": "tdi_effort_change_12m",
      "name": "TDI magnitude of effort change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": 0.8,
            "sd": 1.9,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": -0.7,
            "sd": 1.5,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": 1.5,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": true
      },
      "analysis": {
        "model": "ANCOVA",
        "adjusted": true,
        "covariates": [
          "baseline value"
        ],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "TDI magnitude of effort change: 0.8 ± 1.9 (Zephyr) vs -0.7 ± 1.5 (SoC); Δ 1.5; P < 0.001"
      }
    },
    {
      "concept_id": "tdi_functional_impairment_change_12m",
      "name": "TDI functional impairment change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": 0.7,
            "sd": 1.8,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": -0.7,
            "sd": 1.6,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": 1.4,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": true
      },
      "analysis": {
        "model": "ANCOVA",
        "adjusted": true,
        "covariates": [
          "baseline value"
        ],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "TDI functional impairment change: 0.7 ± 1.8 (Zephyr) vs -0.7 ± 1.6 (SoC); Δ 1.4; P < 0.001"
      }
    },
    {
      "concept_id": "cat_q5_activity_change_12m",
      "name": "CAT Q5 (limited activities at home) change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -0.7,
            "sd": 1.7,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 0.0,
            "sd": 1.3,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -0.7,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "CAT Q5 activity change: -0.7 ± 1.7 (Zephyr) vs 0.0 ± 1.3 (SoC); Δ -0.7; P < 0.001"
      }
    },
    {
      "concept_id": "sgrq_activity_change_12m",
      "name": "SGRQ activity domain change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -12.0,
            "sd": 21.46,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 0.7,
            "sd": 14.31,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -12.7,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.001,
        "p_operator": "<",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "SGRQ activity domain change: -12.0 ± 21.46 (Zephyr) vs 0.70 ± 14.31 (SoC); Δ -12.7; P < 0.001"
      }
    },
    {
      "concept_id": "sgrq_total_change_12m",
      "name": "SGRQ total score change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -7.55,
            "sd": 15.71,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": -0.5,
            "sd": 15.5,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -7.05,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.004,
        "p_operator": "=",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "SGRQ total score change: -7.55 ± 15.71 (Zephyr) vs -0.50 ± 15.50 (SoC); Δ -7.05; P = 0.004"
      }
    },
    {
      "concept_id": "sgrq_impacts_change_12m",
      "name": "SGRQ impacts domain change from baseline",
      "type": "continuous",
      "outcome_type": "secondary",
      "timepoint_iso8601": "P12M",
      "unit": "points",
      "unit_canonical": "points",
      "groups": [
        {
          "arm_id": "intervention",
          "raw": {
            "mean": -9.58,
            "sd": 19.0,
            "total": 128
          }
        },
        {
          "arm_id": "control",
          "raw": {
            "mean": 0.14,
            "sd": 17.34,
            "total": 62
          }
        }
      ],
      "comparison": {
        "ref_arm_id": "control",
        "measure": "mean_difference",
        "est": -9.72,
        "ci_lower": null,
        "ci_upper": null,
        "p_value": 0.004,
        "p_operator": "=",
        "adjusted": false
      },
      "analysis": {
        "model": "Wilcoxon rank-sum",
        "adjusted": false,
        "covariates": [],
        "population": "Available cases at 12 months",
        "missing_handling": "Not specified for PROs (post hoc)"
      },
      "provenance": {
        "pages": [],
        "tables": [
          "Table 1"
        ],
        "quote": "SGRQ impacts domain change: -9.58 ± 19.00 (Zephyr) vs 0.14 ± 17.34 (SoC); Δ -9.72; P = 0.004"
      }
    }
  ],
  "safety_normalized": [],
  "risk_of_bias": {
    "tool": "RoB 2",
    "overall_judgment": "some concerns",
    "domains": [
      {
        "name": "Randomization process",
        "judgment": "low",
        "support_for_judgment": "2:1 randomization reported; multicenter RCT."
      },
      {
        "name": "Deviations from intended interventions",
        "judgment": "some concerns",
        "support_for_judgment": "Open-label design; participants and assessors not blinded."
      },
      {
        "name": "Missing outcome data",
        "judgment": "some concerns",
        "support_for_judgment": "12 subjects did not complete 12-month assessments; imputation not specified for post hoc PROs."
      },
      {
        "name": "Measurement of the outcome",
        "judgment": "some concerns",
        "support_for_judgment": "Self-reported PROs without blinding may introduce bias."
      },
      {
        "name": "Selection of the reported result",
        "judgment": "some concerns",
        "support_for_judgment": "Inferential statistics for PROs were post hoc."
      }
    ]
  },
  "retrieval": {
    "keywords": [
      "emphysema",
      "COPD",
      "endobronchial valve",
      "Zephyr",
      "bronchoscopic lung volume reduction",
      "patient-reported outcomes",
      "dyspnea",
      "SGRQ",
      "CAT",
      "TDI"
    ],
    "summary_tldr": "In patients with severe heterogeneous emphysema and minimal collateral ventilation, Zephyr endobronchial valves produced clinically meaningful 12-month improvements in dyspnea, activity, and quality-of-life measures versus standard care.",
    "clinical_relevance": "Demonstrates sustained, multidimensional patient-reported benefits of Zephyr valves at 12 months, complementing physiologic improvements."
  }
}